Allarity Therapeutics to Present at Biomarkers 2024
February 28 2024 - 5:00AM
Boston (February 28, 2024) —
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ:
ALLR), a clinical-stage pharmaceutical company dedicated to
developing personalized cancer treatments, is pleased to announce
that it has been invited to present at Biomarkers 2024.
Thomas Jensen, CEO and co-founder of Allarity, will present the
company's novel work in developing the drug-specific Drug Response
Predictor (DRP®) companion diagnostics (CDx) platform. This work
spans from cancer cell line research to the validation of concepts
through retrospective clinical data analysis and into the area of
prospective clinical trials, notably an ongoing trial for ovarian
cancer. This trial investigates how a DRP® created specifically for
the Company’s lead clinical asset, the dual PARP/Tankyrase
inhibitor stenoparib, can be used to pre-select advanced ovarian
cancer patients who are predicted to have a significant likelihood
of clinical benefit from treatment for enrollment in this phase 2
monotherapy study, NCT03878849. The study is being conducted at
multiple sites across the US and Europe.
Presentation details:
Event: Biomarkers 2024Presentation title: A Gene Expression
Based Biomarker For Predicting Response To TreatmentDate: February
29, 2024Location: London, UKWeb:
https://oxfordglobal.com/biomarkers/events/biomarkers-2024
Mr. Jensen will be available for individual meetings to explore
business development prospects. Attendees are encouraged to book
one-on-one sessions in advance.
About the Drug Response Predictor –
DRP® Companion
Diagnostic Allarity uses its drug-specific
DRP® to select those patients who, by the
expression signature of their cancer, are found to have a high
likelihood of benefiting from a specific drug. By screening
patients before treatment, and only treating those patients with a
sufficiently high, drug-specific DRP score, the therapeutic benefit
rate may be significantly increased. The DRP method builds on the
comparison of sensitive vs. resistant human cancer cell lines,
including transcriptomic information from cell lines combined with
clinical tumor biology filters and prior clinical trial outcomes.
DRP is based on messenger RNA expression profiles from patient
biopsies. The DRP® platform has proven its ability
to provide a statistically significant prediction of the clinical
outcome from drug treatment in cancer patients in 37 out of 47
clinical studies that were examined (both retrospective and
prospective). The DRP platform, which can be used in all cancer
types and is patented for more than 70 anti-cancer drugs, has been
extensively published in the peer-reviewed literature.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage
biopharmaceutical company dedicated to developing personalized
cancer treatments. The Company is focused on development of
stenoparib, a novel PARP/Tankyrase inhibitor for advanced ovarian
cancer patients, using its DRP® companion diagnostic for patient
selection in the ongoing phase 2 clinical trial, NCT03878849.
Allarity is headquartered in the U.S., with a research facility in
Denmark, and is committed to addressing significant unmet medical
needs in cancer treatment. For more information, visit
www.Allarity.com.
Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/
X: https://twitter.com/allaritytx
Forward-Looking Statements This press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements provide Allarity’s current expectations
or forecasts of future events. The words “anticipates,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intends,” “may,”
“might,” “plan,” “possible,” “potential,” “predicts,” “project,”
“should,” “would” and similar expressions may identify
forward-looking statements, but the absence of these words does not
mean that a statement is not forward-looking. These forward-looking
statements include, but are not limited to, statements related to
the expected availability of capital to fund its anticipated
clinical trials, statements related to advancing dovitinib in
combination with stenoparib or another therapeutic candidate or
other approved drug, any statements related to ongoing clinical
trials for stenoparib as a monotherapy or in combination with
another therapeutic candidate for the treatment of advanced ovarian
cancer, or ongoing clinical trials (in Europe) for
IXEMPRA® for the treatment of metastatic breast cancer,
statements relating to the effectiveness of the Company’s
DRP® companion diagnostics platform in predicting whether a
particular patient is likely to respond to a specific drug, and
statements related to the Company’s ability to regain compliance
with the Nasdaq Listing Rule. Any forward-looking statements in
this press release are based on management’s current expectations
of future events and are subject to multiple risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risk that the Company is not able to
raise sufficient capital to support its current and anticipated
clinical trials, the risk that early results of a clinical
study do not necessarily predict final results and that one or more
of the clinical outcomes may materially change following more
comprehensive reviews of the data, and as more patient data become
available, the risk that results of a clinical study are subject to
interpretation and additional analyses may be needed and/or may
contradict such results, the receipt of regulatory approval for
stenoparib, dovitinib or any of our other therapeutic
candidates and companion diagnostics or, if approved, the
successful commercialization of such products, the risk of
cessation or delay of any of the ongoing or planned clinical trials
and/or our development of our product candidates, the risk that the
results of previously conducted studies will not be repeated or
observed in ongoing or future studies involving our therapeutic
candidates, and the risk that the current COVID-19 pandemic will
impact the Company’s current and future clinical trials and the
timing of the Company’s preclinical studies and other operations.
For a discussion of other risks and uncertainties, and other
important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see
the section entitled “Risk Factors” in our Form S-1 registration
statement filed on October 30, 2023, as amended and our Form 10-K
annual report on file with the Securities and Exchange
Commission, available at the Securities and Exchange Commission’s
website at www.sec.gov, and as well as discussions of
potential risks, uncertainties and other important factors in the
Company’s subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and the Company undertakes no duty to update this
information unless required by law.
###
Company Contact:
investorrelations@allarity.com
Media
Contact: Thomas
Pedersen Carrotize
PR &
Communications +45
6062
9390 tsp@carrotize.com
- Allarity Therapeutics to Present at Biomarkers 2024
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
From Jan 2025 to Feb 2025
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
From Feb 2024 to Feb 2025
